Anti-VEGF medicine with PRP for neovascular glaucoma

• Main Authors: Yue Deng, Jin-Sha Zhang
• Format: Article
• Language: English
• Published: Press of International Journal of Ophthalmology (IJO PRESS) 2018-10-01
• Series: Guoji Yanke Zazhi
• Subjects: neovascular glaucoma; vascular endothelial growth factor; platelet-derived growth factor-C
• Online Access: http://ies.ijo.cn/cn_publish/2018/10/201810023.pdf
• ISSN: 1672-5123; 1672-5123

AIM:To investigate the effect of anti-vascular endothelial growth factor(VEGF)combined with pan retinal photocoagulation(PRP)on neovascular glaucoma(NVG)and its effect on VEGF and platelet-derived growth factor-C(PDGF-C)in aqueous humor. <p>METHODS: A total of 90 patients with NVG(93 eyes)who underwent examination and treatment in our hospital from November 2016 to November 2017 were randomly divided into control group and observation group. The control group was treated with PRP, and the observation group was treated with laser photocoagulation combined with vitreous injection of ranibizumab. The clinical efficacy, iris neovascularization and visual recovery were compared between the two groups after treatment. And we compared the retinal vein circulation time, intraocular pressure, retinal nerve fiber layer thickness, visual field defect value, VEGF and PDGF-C levels in aqueous humor and adverse reactions before and after treatment. <p>RESULTS: At 1mo after treatment, the clinical efficacy, iris neovascularization and visual recovery were better than the control group(<i>P</i><0.05). After treatment, the retinal vein circulation time, intraocular pressure, visual field defect, aqueous humor VEGF and PDGF-C levels were significantly lower in the observation group than in the control group, and RNFL was significantly higher than the control group(<i>P</i><0.05). There was no significant difference in the incidence of adverse reactions between the two groups(<i>P</i>>0.05). <p>CONCLUSION: The use of PRP combined with anti-VRGF drugs for NVG can inhibit angiogenesis and restore retinal function more effectively, which may be better because the combination therapy has better down-regulation of VEGF and PDGF-C.